ANI Pharmaceuticals (NASDAQ:ANIP) Announces Quarterly Earnings Results, Beats Expectations By $0.77 EPS

ANI Pharmaceuticals (NASDAQ:ANIP) posted its quarterly earnings data on Friday. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77, FiscalAI reports. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the firm posted $1.70 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2026 guidance to 9.190-9.690 EPS.

Here are the key takeaways from ANI Pharmaceuticals’ conference call:

• ANI raised its 2026 guidance, now targeting $1.08B–$1.14B in revenue, $285M–$300M adjusted EBITDA and $9.19–$9.69 adjusted EPS, driven by rare disease strength.
• Cortrophin Gel revenue grew 42% YoY to $75.1M in Q1, April saw the highest new patient starts since launch, and a 64?rep commercial expansion into primary care and podiatry is being deployed to accelerate H2/2026 and 2027 growth.
• ANI recognized a $15M upfront fee from an out?license to Harmony Biosciences, expects an additional $10M in near?term development milestones (Q2–Q3) and low?single?digit royalties on pitolisant (WAKIX), adding immediate cash and future royalty upside.
• Generics continue to fund growth with Q1 generics revenue of $105.4M (up 7%), six new launches YTD and a steady 10–15 launch cadence, while management authorized a new $100M share repurchase program as part of disciplined capital allocation.
• Q1 results were impacted by insurance reverification delays and weather?related office closures that temporarily depressed early?quarter Cortrophin volumes and contributed to a lower non?GAAP gross margin (60.8%), and ILUVIEN still faces ongoing Medicare access challenges.

ANI Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ ANIP opened at $81.86 on Friday. The firm’s 50 day moving average price is $76.82 and its 200-day moving average price is $81.01. The company has a market cap of $1.83 billion, a PE ratio of 20.72 and a beta of 0.46. ANI Pharmaceuticals has a 52-week low of $56.71 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 1.11, a quick ratio of 2.19 and a current ratio of 2.71.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,312 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $75.50, for a total value of $552,056.00. Following the transaction, the chief financial officer owned 185,543 shares in the company, valued at approximately $14,008,496.50. This represents a 3.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Thomas Andrew Rowland sold 4,772 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares in the company, valued at approximately $2,901,264.30. This represents a 10.97% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 27,860 shares of company stock valued at $2,111,581. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Advisors Asset Management Inc. bought a new position in shares of ANI Pharmaceuticals in the first quarter worth approximately $28,000. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. State of Wyoming purchased a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Tower Research Capital LLC TRC raised its holdings in shares of ANI Pharmaceuticals by 542.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,727 shares of the specialty pharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,458 shares during the last quarter. Finally, Vestcor Inc purchased a new position in shares of ANI Pharmaceuticals during the third quarter valued at approximately $213,000. Institutional investors own 76.05% of the company’s stock.

Trending Headlines about ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.